S100A8/A9中和抗体显著改善接触性超敏反应与特应性皮炎症状
该研究开发了靶向S100A8/A9的抑制性抗体Ab45及其人源化版本HuAb45。在多种模型中,Ab45有效预防疾病症状,其作用可能涉及下调Il-23a、Il-36g、S100a8和S100a9等疾病相关分子。HuAb45表现出相似效果,提示这些抗体有望用于治疗接触性超敏反应和特应性皮炎,并可能适用于其他炎症性皮肤病。
要点
- Ab45在多种模型中有效预防接触性超敏反应和特应性皮炎症状。
- Ab45的疾病改善活性可能与下调Il-23a、Il-36g、S100a8和S100a9有关。
- 人源化抗体HuAb45表现出与Ab45相似的有效性。
核心结论
- Ab45和HuAb45有望用于治疗接触性超敏反应和特应性皮炎,并可能适用于其他炎症性皮肤病。
研究设计与样本
- 本研究在多种模型中验证了Ab45对疾病症状的预防效果,并开发了人源化版本HuAb45。
主要发现
- Ab45有效预防了多种模型中的疾病症状。
- Ab45的疾病改善活性可能涉及下调Il-23a、Il-36g、S100a8和S100a9。
- HuAb45表现出与Ab45相似的有效性。
临床怎么用
- 这些抗体可能为接触性超敏反应和特应性皮炎提供新的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Contact hypersensitivity and atopic dermatitis are pervasive inflammatory skin diseases with similar symptoms, and their global prevalence is steadily increasing. Many compounds and biotics have been developed to target molecules critical to the etiology or pathogenesis of contact hypersensitivity and atopic dermatitis. However, these molecules are sometimes ineffective or lose their potency during the therapeutic course. Therefore, innovative medicines are still needed for the treatment of intractable cases. We focused on S100A8/A9, a heterodimer complex of S100A8 and S100A9 that is abundant in the extracellular milieu of inflammatory skin lesions. Although S100A8/A9 is primarily recognized as a diagnostic marker protein, we have previously shown that it also plays a crucial role in contact hypersensitivity and atopic dermatitis progression. This insight inspired us to develop its inhibitory antibody, leading to the ground-breaking Ab45. In this study, we demonstrated that Ab45 effectively prevented disease symptoms in various models and that its disease-ameliorating activity likely involved the downregulation of several disease-relevant molecules, including Il-23a, Il-36g, S100a8, and S100a9. We also created a humanized version of Ab45, HuAb45, which exhibited similar effectiveness. These antibodies show great promise for the treatment of contact hypersensitivity and atopic dermatitis and possibly for other inflammatory skin diseases.
引用
- Gohara Y, Kinoshita R, Tomonobu N, et al. An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms. J Invest Dermatol. 2025. PMID: 39848567. doi:10.1016/j.jid.2025.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。